

THE BEST OF THE WEEK (17 ott – 23 ott 2022)

K. Tsun-Yung et al.

Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants

bioRxiv, October 2022; doi.org/10.1101/2022.10.07.511263

Abstract

The dominance of SARS-CoV-2 variants of concern (VoC), such as the Omicron subvariants, is a threat to the current vaccination scheme. Boosting with bivalent mixture of Omicron BA.4/BA.5 and W S-2P achieved the highest neutralizing antibody titers against BA.4/BA.5 subvariant pseudovirus compared to other types of S-2P as boosters.

S. Collie et al.

Effectiveness and durability of the BNT162B2 vaccine against Omicron sublineages in South Africa

New England J of Medicine, October 2022; doi: 10.1056/NEJMc2210093

Abstract

Data are limited regarding the effectiveness of the BNT162b2 vaccine (Pfizer–BioNTech) against the BA.4 and BA.5 sublineages of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the recent fifth wave of infection in South Africa. In this analysis, the authors separately assessed the effectiveness and durability of the BNT162b2 vaccine against BA.1 or BA.2 and against BA.4 or BA.5 among members of Discovery Health, a medical care organization.